JGP Wealth Management LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 651 shares of the life sciences company’s stock, valued at approximately $241,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in ILMN. Carroll Financial Associates Inc. acquired a new stake in Illumina during the second quarter valued at approximately $32,000. TFG Advisers LLC acquired a new stake in Illumina during the fourth quarter valued at approximately $33,000. Total Clarity Wealth Management Inc. acquired a new stake in Illumina during the fourth quarter valued at approximately $33,000. Bainco International Investors bought a new position in shares of Illumina during the first quarter valued at approximately $33,000. Finally, Capital Square LLC bought a new position in shares of Illumina during the first quarter valued at approximately $36,000. Hedge funds and other institutional investors own 89.86% of the company’s stock.
In other Illumina news, SVP Phillip G. Febbo sold 173 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $300.00, for a total transaction of $51,900.00. Following the completion of the transaction, the senior vice president now directly owns 2,490 shares of the company’s stock, valued at approximately $747,000. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jay T. Flatley sold 4,000 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $370.22, for a total value of $1,480,880.00. Following the transaction, the director now directly owns 230,933 shares of the company’s stock, valued at $85,496,015.26. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 36,058 shares of company stock valued at $12,074,638. 0.38% of the stock is currently owned by corporate insiders.
Several research firms have recently commented on ILMN. Cowen upped their target price on Illumina from $275.00 to $320.00 and gave the company an “outperform” rating in a report on Friday, May 1st. Robert W. Baird lowered Illumina from an “outperform” rating to a “neutral” rating and set a $310.00 target price for the company. in a report on Tuesday, April 21st. Barclays lowered their target price on Illumina from $390.00 to $350.00 and set an “overweight” rating for the company in a report on Thursday, March 26th. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and upped their target price for the company from $250.00 to $320.00 in a report on Friday, April 24th. They noted that the move was a valuation call. Finally, Argus upped their target price on Illumina from $340.00 to $380.00 in a report on Thursday, May 21st. Two analysts have rated the stock with a sell rating, five have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $340.50.
Shares of ILMN stock opened at $369.13 on Tuesday. The business has a 50 day simple moving average of $362.04 and a 200 day simple moving average of $314.38. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.10 and a quick ratio of 3.74. The firm has a market capitalization of $54.43 billion, a price-to-earnings ratio of 58.13, a price-to-earnings-growth ratio of 5.48 and a beta of 1.00. Illumina, Inc. has a 12-month low of $196.78 and a 12-month high of $384.21.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.39. The firm had revenue of $859.00 million during the quarter, compared to analyst estimates of $857.92 million. Illumina had a return on equity of 21.78% and a net margin of 26.48%. The firm’s quarterly revenue was up 1.5% on a year-over-year basis. During the same period last year, the company posted $1.60 EPS. On average, equities analysts anticipate that Illumina, Inc. will post 6.15 EPS for the current fiscal year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Featured Article: Municipal Bonds
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.